Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison

Michelle D. Kelsey, Adam J. Nelson, Jennifer B. Green, Christopher B. Granger, Eric D. Peterson, Darren K. McGuire, Neha J. Pagidipati

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatment, glycemic control, kidney protection, and lifestyle intervention. There are several recommendation and guideline documents across cardiology, endocrinology, nephrology, and general medicine professional societies from the United States and Europe with recommendations for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Although there are some noteworthy differences, particularly in risk stratification, low-density lipoprotein-cholesterol and blood pressure treatment targets, and the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, overall there is considerable alignment across recommendations from different professional societies.

Original languageEnglish (US)
Pages (from-to)1849-1857
Number of pages9
JournalJournal of the American College of Cardiology
Issue number18
StatePublished - May 10 2022


  • guidelines
  • prevention
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison'. Together they form a unique fingerprint.

Cite this